The Annual General Meeting took place at the Congress Center Messe Frankfurt, Ludwig-Erhard-Anlage 1, 60327 Frankfurt am Main, Germany on Thursday, May 12, 2016.
Fresenius Medical Care, the world’s leading provider of dialysis products and services, expects significant sales and earnings growth in 2016. At the Annual General Meeting in Frankfurt today, CEO Rice Powell confirmed the full-year guidance announced in February. The company is targeting 7 to 10 percent revenue growth in constant currency, and an increase in net income of 15 to 20 percent. Powell also confirmed Fresenius Medical Care’s long-term financial goals: Revenue of $28 billion is targeted for 2020, corresponding to an average growth rate of about 10 percent. Over the same period, an annual, high single-digit percent increase in net income is expected.
A large shareholder majority of 99.96 percent approved the company’s 19th consecutive dividend increase. The dividend will be raised from €0.78 to €0.80 per share.
All candidates for the new term of the Supervisory Board were elected by the shareholders with clear majorities. Joining the Board for the first time are Deborah Doyle McWhinney, former Chief Executive Officer and Chief Operating Officer of Citi Enterprise Payments (Citigroup, Inc.), and Pascale Witz, Executive Vice President, Global Diabetes & Cardiovascular at Sanofi S.A.
Shareholder majorities of 99.92%, respectively, approved the actions of the Management and Supervisory Boards in 2015.
We have every reason to look to the future with great confidence.
In the past year, we have positioned ourselves to continue the unique success story of Fresenius Medical Care in the years to come. We will continue to grow our dialysis services and products business while actively shaping the development of the dialysis market. We are extending our range of related medical services in the area of Care Coordination.